Abstract
Antibodies have become the preferred therapeutic treatment option for cancers. Antibody therapy is associated with low toxic profile and specific in its activity, unlike chemotherapy and radiotherapy. Types of tumor are known to express multiple receptors that cross-talk to activate perpetual growth, proliferation and metastasis, and inhibit apoptosis in such tumors. Bispecific antibodies (BsAbs) are therefore the preferred agent for the treatment of such cancers due to its unique characteristics. This review discusses up to date therapeutic potentials of BsAbs.
Keywords: Antibody, bispecific antibody (BsAb), immunotherapeutic agent, cancer therapy, diabody, antitumor.
Protein & Peptide Letters
Title:Bispecific Antibodies (bsAbs): Promising Immunotherapeutic Agents for Cancer Therapy
Volume: 24 Issue: 5
Author(s): Deasmond O. Acheampong*, Christian K. Adokoh*, Paulina Ampomah, Daniel S. Agyirifor, Isaac Dadzie, Francis A. Ackah and Ernest A. Asiamah
Affiliation:
- Department of Biomedical Sciences, School of Allied Health Sciences, University of Cape Coast, Cape Coast,Ghana
- Department of Forensic Sciences, School of Biological Sciences, University of Cape Coast, Cape Coast,Ghana
Keywords: Antibody, bispecific antibody (BsAb), immunotherapeutic agent, cancer therapy, diabody, antitumor.
Abstract: Antibodies have become the preferred therapeutic treatment option for cancers. Antibody therapy is associated with low toxic profile and specific in its activity, unlike chemotherapy and radiotherapy. Types of tumor are known to express multiple receptors that cross-talk to activate perpetual growth, proliferation and metastasis, and inhibit apoptosis in such tumors. Bispecific antibodies (BsAbs) are therefore the preferred agent for the treatment of such cancers due to its unique characteristics. This review discusses up to date therapeutic potentials of BsAbs.
Export Options
About this article
Cite this article as:
Acheampong O. Deasmond*, Adokoh K. Christian*, Ampomah Paulina, Agyirifor S. Daniel, Dadzie Isaac, Ackah A. Francis and Asiamah A. Ernest, Bispecific Antibodies (bsAbs): Promising Immunotherapeutic Agents for Cancer Therapy, Protein & Peptide Letters 2017; 24 (5) . https://dx.doi.org/10.2174/0929866524666170120095128
DOI https://dx.doi.org/10.2174/0929866524666170120095128 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Issues in the Psychiatric Screening of Cancer Patients
Current Psychiatry Reviews Microsatellite Instability as a Predictor of Outcomes in Colorectal Cancer in the Era of Immune-Checkpoint Inhibitors
Current Drug Targets Patent Selections:
Recent Patents on Biomarkers Drug Targeting Strategies for Photodynamic Therapy
Anti-Cancer Agents in Medicinal Chemistry Pharmacophore Modeling and 3D QSAR Studies of Novel Human Carbonic Anhydrase IX Inhibitors
Letters in Drug Design & Discovery Bioplex Technology: Novel Synthetic Gene Delivery Pharmaceutical Based on Peptides Anchored to Nucleic Acids
Current Pharmaceutical Design An Update on the Systemic Therapy of Malignant Salivary Gland Cancers: Role of Chemotherapy and Molecular Targeted Agents
Current Medicinal Chemistry - Anti-Cancer Agents Antibodies as Crypts of Antiinfective and Antitumor Peptides
Current Medicinal Chemistry Imaging Agents in Targeting Tumor Hypoxia
Current Medicinal Chemistry Editorial [ The Role of Epidermal Growth Factor Receptor (EGFR) Targeting Drugs in the Treatment of Cancer Guest Editor: Fortunato Ciardiello ]
Current Cancer Therapy Reviews Peptides to Target Tumor Vasculature and Lymphatics for Improved Anti-Angiogenesis Therapy
Current Cancer Drug Targets Interaction of ABC Multidrug Transporters with Anticancer Protein Kinase Inhibitors: Substrates and/or Inhibitors?
Current Cancer Drug Targets Novel Therapeutic Strategies in Infection and Cancer Management
Current Aging Science The Role of COX-2 in Oral Cancer Development, and Chemoprevention/ Treatment of Oral Cancer by Selective COX-2 Inhibitors
Current Pharmaceutical Design Brain Tumour Stem Cells: Implications for Cancer Therapy and Regenerative Medicine
Current Stem Cell Research & Therapy Growth Factors, Cytokines and Dendritic Cell Development
Current Pharmaceutical Design Prospects for Hypoxia-Activated Anticancer Drugs
Current Medicinal Chemistry - Anti-Cancer Agents Histone Deacetylase Inhibitors: An Attractive Strategy for Cancer Therapy
Current Medicinal Chemistry Intraperitoneal Oncolytic and Tumor Vaccination Therapy with Replication-Competent Recombinant Virus: The Herpes Paradigm
Current Gene Therapy Newer Insights in Personalized and Evidence Based Medicine- the Role of MicroRNAs
Current Pharmacogenomics and Personalized Medicine